Faecal microbiota transplantation (FMT) is a highly effective treatment for diseases where the intestinal microbiota is compromised, particularly Clostridioides difficile infection. Encapsulated FMT offers a scalable and non-invasive treatment option that requires less hands-on personnel compared to other application methods, while achieving effect rates similar to colonoscopy-based FMT for recurrent Clostridioides difficile infections (rCDI). In this study, the authors from Aarhus University Hospital, Denmark, describe the Glyprotect protocol for preparing glycerol-conserved, encapsulated FMT [1]. Tailored for standard-equipped laboratories, the protocol is validated and reproducible, adhering to stringent quality standards and legislative requirements. The microbiota concentrate is double encapsulated in Capsugel® Enprotect® (inner) and Capsugel® Vcaps® Plus capsules (outer), both validated by the authors to ensure their compatibility for oral delivery of glycol-conserved faecal preparations. This protocol is optimized to preserve microbes and minimize alterations to the donated microbiota by removing debris and water, which also reduces the number of capsules required per FMT treatment.
Related:
Capsugel® Enprotect® Capsules
Capsugel® Enprotect® brochure
Reference:
1. Hansen MM, Rågård N, Andreasen PW, Paaske SE, Dahlerup JF, Mikkelsen S, Erikstrup C, Baunwall SMD, Hvas CL. Encapsulated donor faeces for faecal microbiota transplantation: the Glyprotect protocol. Therap Adv Gastroenterol. 2024 Oct 13;17:17562848241289065. doi: 10.1177/17562848241289065. PMID: 39421003; PMCID: PMC11483698.
Article credit: Encapsulated donor faeces for faecal microbiota transplantation: the Glyprotect protocol - PubMed